Showing 1 to 2 of 2 results


FDA Suspends Chikungunya Vaccine Ixchiq Due to Severe Side Effects
The U.S. FDA suspended the chikungunya vaccine Ixchiq due to new reports of severe side effects in four patients aged 55-82, halting U.S. sales and distribution; this follows previous suspensions in France and the EU, raising concerns about its future.
FDA Suspends Chikungunya Vaccine Ixchiq Due to Severe Side Effects
The U.S. FDA suspended the chikungunya vaccine Ixchiq due to new reports of severe side effects in four patients aged 55-82, halting U.S. sales and distribution; this follows previous suspensions in France and the EU, raising concerns about its future.
Progress
44% Bias Score

FDA Suspends Chikungunya Vaccine License Due to Serious Side Effects
The U.S. FDA suspended the license for the Ixchiq chikungunya vaccine due to four reports of adverse events, three of which were serious and occurred in individuals aged 70-82. This follows the EMA's initiation of a review and comes amid a WHO warning of a potential large chikungunya outbreak.

FDA Suspends Chikungunya Vaccine License Due to Serious Side Effects
The U.S. FDA suspended the license for the Ixchiq chikungunya vaccine due to four reports of adverse events, three of which were serious and occurred in individuals aged 70-82. This follows the EMA's initiation of a review and comes amid a WHO warning of a potential large chikungunya outbreak.
Progress
40% Bias Score
Showing 1 to 2 of 2 results